Clinical Chemistry, Vol 41, 1844-1847, Copyright © 1995 by American Association for Clinical Chemistry

Serum oncoproteins in asbestosis patients

R Partanen, H Koskinen, P Oksa, K Hemminki, W Carney, S Smith and P Brandt-Rauf
Center for Nutrition and Toxicology, Karolinska Institute, Huddinge, Sweden.

Using ELISAs, we determined the concentrations of transforming growth factor alpha (TGF-alpha), the extracellular domain of the erbB-2 receptor (erbB-2 ECD), and mutant p53 protein in stored serum samples of asbestosis patients with and without cancer and control subjects (without asbestosis or cancer). The percentage of individuals in these three groups with increased serum concentrations of TGF-alpha, erbB-2 ECD, and mutant p53, respectively, were: asbestosis patients with cancer, 36%, 16%, 19%; asbestosis patients without cancer, 38%, 19%, 6%; control subjects, 0%, 5%, 10%. Although differences in serum positivity for these oncoproteins were apparent among these groups, the differences did not achieve statistical significance (P > 0.05). In several of the cancer cases, increased concentrations of TGF-alpha, erbB-2 ECD, and mutant p53 were also detected in the stored serum samples collected years before the clinical diagnosis of disease.

The following articles in journals at HighWire Press have cited this article:

				J Shaham, Y Bomstein, R Gurvich, M Rashkovsky, and Z Kaufman DNA-protein crosslinks and p53 protein expression in relation to occupational exposure to formaldehyde Occup. Environ. Med., June 1, 2003; 60(6): 403 - 409. [Abstract] [Full Text] [PDF]

				T. Soussi p53 Antibodies in the Sera of Patients with Various Types of Cancer: A Review Cancer Res., April 1, 2000; 60(7): 1777 - 1788. [Abstract] [Full Text]